my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
Heidelberg pharmacologists and neurobiologists have discovered a key mechanism for the origin of chronic pain. In patients with persistent pain, calcium in the neurons ensures that these cells establish more contact to other pain-conducting neurons and react more sensitively to painful stimuli on a more
Molecular biologist Michael Karin, professor in the Department of Pharmacology at the University of California in San Diego, is to receive this year’s Charles Rodolphe Brupbacher Prize for Cancer Research in recognition of his studies on the role of chronic inflammation in the development of tumors. more
Zealand Pharma and Pepscan Holding NV announced the joint award of an EU research and development grant of EUR 860,000. The grant is awarded under the EUREKA Eurostars programme for the joint development of dual acting peptide drugs. The application by Zealand Pharma and Pepscan ranked no. 5 out of more
Accumulated data from animal models and human cancer patients strongly support the concept that the immune system can identify and control nascent tumor cells in a process called cancer immunosurveillance. In addition, the immune system can also promote tumor progression through chronic inflammati more
The skin immune system includes a complex network of dendritic cells (DCs). In addition to generating cellular and humoral immunity against pathogens, skin DCs are involved in tolerogenic mechanisms that maintain immune homeostasis and in pathogenic chronic inflammation in which immune responses a more
CD200 and its receptor, CD200 receptor (CD200R), have unique roles in controlling damaging inflammatory processes. At present, the only identified function for CD200 is as a ligand for CD200R. These proteins interact resulting in the activation of anti-inflammatory signaling by CD200R-expressing cel more
Dynavax Technologies Corporation (Dynavax) is a pharmaceutical company that is engaged in the discovery and development of product candidates to prevent and treat infectious diseases. The company's product pipeline includes HEPLISAV, a Phase 3 investigational adult hepatitis B vaccine; AZD1419, a pr more
Oxford Biomedical Research, Inc. (OBR) is engaged in the development and manufacture of immunoassay products, such as ELISA kits for the quantification of bioactive lipids in cells and biological fluids. It manufactures and distributes biological reagents, assay kits and services. The company lays p more
Inflammation is a defense mechanism of the body to protect it from infection and injury. The inflammatory response is started by white blood cells releasing defense molecules to remove injurious stimuli such as damaged cells, pathogens or irritants. Redness, pain, swelling, heat and loss of more
X Enobia Homepage Home | Search | Contact | Français Hypophosphatasia Key Discoveries in the History of HPP Clinical Presentation Diagnosis Pathophysiology Epidemiology Managing HPP Science ENB-0040 Pipeline Glossary Patients About Hypophosphatasia Diagnosing Hypophosphatasia Treating Hypophosphatas more
Corporate Overview History Management Team Board of Directors Collaborators & Advisors Current Investors Overview Therapeutic Areas Pipeline Publications Press Releases Presentations Careers Pipeline CD200 fusion protein (CD200Fc) CD200 is a transmembrane protein broadly expressed on a variety of ce more
Watchlist
This is where you can add this topic to your personal favourites
Über CHEMIE.DE
CHEMIE.DE Information Service GmbH runs specialist scientific internet portals. The secret to our success? We are familiar with what we publish.
Advertising at CHEMIE.DE
Our advertising formats support you in getting your message across to a clearly defined target audience.
© 1997-2013 CHEMIE.DE Information Service GmbH, All rights reserved
Netmeeting
